WallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings & Revenue

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
20.82%
Industry
18.33%
Market
37.62%
NVO's earnings have grown slower (6.46% per year) than the US Biotechnology industry average (19.21%)
Performance
NVO's earnings have grown slower (6.46% per year) than the US market average (19.73%)
Performance
NVO's earnings growth is accelerating - its growth over the last year (20.82%) is above its 5-year compound annual rate (6.46%)
Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
14.27%
Industry
357.14%
Market
20.3%
NVO's revenue has grown slower (3.86% per year) than the US Biotechnology industry average (79.1%)
Performance
NVO's revenue has grown slower (3.86% per year) than the US market average (18.37%)
Performance
NVO's revenue growth is accelerating - its growth over the last year (14.27%) is above its 5-year compound annual rate (3.86%)
Performance

NVO earnings and revenue history

Current Revenue
$20.8B
Current Earnings
$6.9B
Current Profit Margin
33.2%

NVO Return on equity

Current Company
71%
Current Industry
-1.9%
Current Market
49.8%
NVO's Return on Equity (71%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

NVO Return on assets

Current Company
30.8%
Current Industry
-9.6%
Current Market
5.4%
NVO is generating higher Return on Assets (30.8%) than the US Biotechnology industry average (-12.12%)
Performance

NVO Return on capital employed

Current Company
74.69%
Current Industry
-2.2%
NVO's ability to generate Return on Capital (74.69%) has decreased compared to 3 years ago (90.8%)
Performance

Novo Nordisk A S Earnings & Revenue FAQ

What were NVO's earnings last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q4 2020 earnings per share (EPS) of $0.88, up 58.3% year over year. Total Novo Nordisk A S earnings for the quarter were $1.95 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.55.

What was NVO's earnings growth in the past year?

As of Q2 2021, Novo Nordisk A S's earnings has grown 20.82% year over year. This is 2.49 percentage points higher than the US Biotechnology industry earnings growth rate of 18.33%. Novo Nordisk A S's earnings in the past year totalled $6.91 billion.

What was NVO's revenue last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q4 2020 revenue of $6.12 billion up 26.52% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $4.84 billion.

What was NVO's revenue growth in the past year?

As of Q2 2021, Novo Nordisk A S's revenue has grown 14.27% year over year. This is 342.87 percentage points lower than the US Biotechnology industry revenue growth rate of 357.14%. Novo Nordisk A S's revenue in the past year totalled $20.81 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.